Allarity Therapeutics (ALLR) News Today $1.67 +0.18 (+12.35%) As of 02:46 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Allarity Therapeutics, Inc.: Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersMay 16, 2026 | finanznachrichten.deAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple CancersMay 15, 2026 | globenewswire.comAllarity Therapeutics CEO Thomas Jensen to Speak at Precision Medicine Forum Europe 2026May 8, 2026 | quiverquant.comQAllarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in StockholmMay 8, 2026 | globenewswire.comAllarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing CampaignMay 5, 2026 | globenewswire.comAllarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark OfficeApril 27, 2026 | globenewswire.comAllarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall ...April 21, 2026 | markets.businessinsider.comAllarity Therapeutics Reports Full Year 2025 Financial Results and Corporate ProgressMarch 31, 2026 | globenewswire.comAllarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided ChemotherapyMarch 12, 2026 | tipranks.comAllarity closes $20M financing for stenoparib advancementMarch 7, 2026 | finance.yahoo.comAllarity Therapeutics Secures $20 Million Non-Convertible Debt Financing to Extend Cash Runway and Advance Ovarian Cancer TrialMarch 6, 2026 | quiverquant.comQAllarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and CommercializationMarch 6, 2026 | globenewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet NeedFebruary 20, 2026 | finanznachrichten.deAllarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet NeedFebruary 18, 2026 | globenewswire.comAllarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small ...February 3, 2026 | markets.businessinsider.comAllarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for EnrollmentFebruary 3, 2026 | globenewswire.comAllarity CEO says 2026 represents an ‘inflection point’January 1, 2026 | finance.yahoo.comAllarity CEO says 2026 represents an inflection pointDecember 31, 2025 | msn.comAllarity Therapeutics Issues 2025 End of Year CEO Letter to ShareholdersDecember 31, 2025 | globenewswire.comAllarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFODecember 8, 2025 | tipranks.comAllarity Therapeutics, Inc.: Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 14, 2025 | finanznachrichten.deAllarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business UpdatesNovember 14, 2025 | globenewswire.comAllarity Therapeutics Advances Ovarian Cancer Study with 2X-121October 27, 2025 | tipranks.comAscendiant Capital Maintains Allarity Therapeutics (ALLR) Buy RecommendationSeptember 26, 2025 | msn.comAllarity Therapeutics registers 1.56M shares for resaleSeptember 25, 2025 | msn.comAllarity presents new Phase 2 clinical data for StenoparibSeptember 22, 2025 | msn.comAllarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 MonthsSeptember 22, 2025 | globenewswire.comAllarity Therapeutics CEO Thomas Jensen to Present at Biomarkers & Precision Medicine 2025 ConferenceSeptember 17, 2025 | quiverquant.comQAllarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025September 17, 2025 | globenewswire.comAllarity Therapeutics’ Stenoparib Receives FDA Fast TrackAugust 29, 2025 | msn.comAllarity Therapeutics Wins FDA Fast Track Designation for Ovarian Cancer Drug Candidate StenoparibAugust 27, 2025 | msn.comAllarity Therapeutics stock soars after FDA Fast Track designationAugust 26, 2025 | investing.comWhy Did Allarity Therapeutics Stock Double In Value Today?August 26, 2025 | msn.comWhy Is Allarity Therapeutics Stock (ALLR) Up 95% Today?August 26, 2025 | msn.comAllarity Therapeutics shares pop as ovarian cancer therapy recieves FDA Fast Track DesignationAugust 26, 2025 | proactiveinvestors.comAllarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian CancerAugust 26, 2025 | globenewswire.comAllarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New PartnershipsAugust 15, 2025 | globenewswire.comAllarity Therapeutics Delays 10-Q FilingAugust 15, 2025 | msn.comAscendiant Capital Initiates Coverage of Allarity Therapeutics (ALLR) with Buy RecommendationJuly 28, 2025 | msn.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform UtilizationJuly 15, 2025 | finanznachrichten.deAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationJuly 15, 2025 | finance.yahoo.comAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationJuly 15, 2025 | globenewswire.comAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief ...July 9, 2025 | seekingalpha.comAllarity Therapeutics Appoints Jeff Ervin as New Chief Financial OfficerJuly 9, 2025 | nasdaq.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 8, 2025 | finanznachrichten.deAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 7, 2025 | globenewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deAllarity Therapeutics Announces Acceptance of Patent Application for Stenoparib DRP® in Australia - NasdaqJuly 2, 2025 | nasdaq.comAllarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion DiagnosticJune 30, 2025 | finance.yahoo.comAllarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Ovarian Cancer - NasdaqJune 29, 2025 | nasdaq.com Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLR Media Mentions By Week ALLR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼1.000.39▲Average Medical News Sentiment ALLR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼32▲ALLR Articles Average Week Get the Latest News and Ratings for ALLR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Allarity Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Cue Biopharma News Anixa Biosciences News enGene News Upexi News Coya Therapeutics News Promis Neurosciences News NRx Pharmaceuticals News aTyr Pharma News FitLife Brands News Q32 Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
